Neuroendocrine Tumours Clinical Trial
Official title:
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low- to intermediate-grade (Grade 1 or Grade 2), well-differentiated NETs. The study will enroll 4 cohorts of varying NETs, as follows: - Cohort A - NET of lung origin - Cohort B - NET of small bowel origin - Cohort C - NET of non-small bowel, non-pancreas, and non-lung origin - Cohort D - NET of any origin (DDI substudy) All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00323076 -
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT02075606 -
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients
|
Phase 4 | |
| Completed |
NCT00326469 -
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
|
Phase 2 | |
| Terminated |
NCT02788578 -
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours
|
||
| Completed |
NCT01840449 -
Somatuline Predictive Factors in Acromegaly and NET
|
||
| Completed |
NCT02698410 -
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
|
Phase 2 | |
| Active, not recruiting |
NCT02923934 -
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers
|
Phase 2 | |
| Completed |
NCT01673906 -
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
|
Phase 2 |